Numbness, burning, or tingling in someone with diabetes deserves an explanation. Diabetic peripheral neuropathy is one possibility, but vitamin B12 deficiency, thyroid disease, kidney disease, nerve compression, and other problems can produce similar symptoms. More than one cause may be present.
Blood tests help identify contributing conditions; they do not replace a neurological examination or prove that diabetes caused the symptoms. A focused discussion may include a vitamin B12 test, selected methylmalonic acid (MMA), a complete blood count (CBC), thyroid-stimulating hormone (TSH), creatinine with estimated glomerular filtration rate (eGFR), and hemoglobin A1C. Ulta Lab Tests offers access to relevant laboratory options that eligible patients can review with their healthcare professional.
This article focuses on investigating nerve symptoms. For the broader laboratory framework, see Diabetes and Prediabetes Blood Tests. If the diabetes type itself is uncertain, the adult-onset autoimmune diabetes guide addresses that separate question.
Peripheral neuropathy means damage or dysfunction in nerves outside the brain and spinal cord. The common diabetes-related pattern affects the feet and lower legs, often on both sides. People may describe burning, pins and needles, electric sensations, pain from light touch, or reduced awareness of temperature and injury. Hands can also become involved. [1]
The pattern matters. Tingling limited to particular fingers, pain traveling from the back into one leg, or rapidly worsening weakness may require a different evaluation from gradual, symmetrical foot numbness. A clinician asks when symptoms began, how they spread, and whether strength, walking, balance, or daily activities have changed.
Loss of sensation can make a small blister or burn difficult to notice. Looking at the feet, checking footwear, and arranging appropriate foot care remain useful even while blood tests are being considered. Laboratory results cannot show whether a shoe is causing pressure or whether a wound needs treatment.
Discuss new, persistent, or changing symptoms rather than waiting for the next routine diabetes laboratory visit. ADA guidance recommends considering other causes of neuropathy, including nutritional, thyroid, and kidney conditions. Its 2026 comorbidity guidance specifically supports B12 assessment in people with type 1 diabetes who have peripheral neuropathy or unexplained anemia. [2,3]
| Symptom or history | Possible laboratory discussion | What else matters |
|---|---|---|
| Gradual tingling or reduced sensation in both feet | A1C and selected B12, thyroid, and kidney testing | Foot examination, sensation, reflexes, circulation, and symptom duration |
| Metformin use, restricted diet, or previous stomach or intestinal surgery | Vitamin B12; MMA if clarification is needed | Diet, absorption, medicines, and supplement history |
| Fatigue, pallor, or previously abnormal blood counts | CBC and targeted nutrient testing | Anemia can have multiple causes; its absence does not exclude nerve involvement |
| Cold intolerance, constipation, or an autoimmune thyroid history | TSH; selected free T4 | Symptoms overlap with many conditions |
| Known kidney disease or an unexplained MMA elevation | Creatinine and reported eGFR | Kidney clearance changes interpretation; advanced kidney disease can affect nerves |
| One-sided symptoms, loss of strength, or rapid progression | Tests selected after prompt clinical assessment | A neurological or structural cause may need specialist investigation |
Seek emergency care for sudden one-sided weakness or numbness, facial drooping, or difficulty speaking. New substantial weakness or difficulty walking needs prompt assessment. A red, hot, swollen foot, an open wound, or signs of infection also deserves urgent clinical advice, particularly when sensation is reduced. Do not wait for an online laboratory order to address these problems.
The following tests are options for particular questions, not a required neuropathy panel. Recent results may already answer some of them.
| Test | What it measures and when useful | Result meaning and limits |
|---|---|---|
| Vitamin B12 test | Circulating vitamin concentration; useful when deficiency could contribute to nerve symptoms | A low result supports deficiency. An indeterminate result may need clarification. Supplements can raise the measured concentration. |
| Methylmalonic acid (MMA) | A metabolite that may accumulate when B12-dependent metabolism is impaired; a selective follow-up test | An elevated value can support deficiency, but kidney impairment also raises it. A low result is generally not a deficiency signal. |
| Complete blood count (CBC) with differential and platelets | Blood-cell counts, hemoglobin, and red-cell indices; adds anemia context | Low hemoglobin or enlarged red cells may support further investigation. Normal counts do not exclude B12-related nerve symptoms. |
| Thyroid-stimulating hormone (TSH) | The pituitary signal controlling thyroid hormone production; useful for suspected thyroid dysfunction | A high or low result requires thyroid-context interpretation. It does not independently diagnose a neurological condition. |
| Free T4 | Unbound thyroxine; added when thyroid results or the clinical setting require clarification | High or low values are interpreted with TSH, medicines, illness, and laboratory method. |
| Creatinine with reported eGFR | A blood waste-product measurement and calculated estimate of kidney filtration | Higher creatinine or lower eGFR can suggest impaired filtration. Muscle mass, hydration, and other factors influence interpretation. |
| Hemoglobin A1C | Glucose exposure over roughly two to three months; supports diabetes follow-up | A higher result may show greater recent exposure. A lower result does not exclude prior nerve injury or another cause of symptoms. |
A separate, potentially treatable contributor can coexist with diabetic nerve damage. Risk assessment includes dietary intake, absorption disorders, gastrointestinal surgery, and medicines such as metformin. Autoimmune conditions can also cluster in people with type 1 diabetes.
Neurological B12 deficiency does not require a low hemoglobin or an enlarged average red-cell size. When symptoms and an initial result leave uncertainty, MMA may help. Kidney function and recent replacement treatment should be considered before interpreting that additional result. [4,5]
For the detailed deficiency and cause-investigation pathway, see Vitamin B12 Deficiency and Autoimmune Gastritis. This symptom-focused article does not make autoimmune antibody testing a routine next step for everyone with tingling.
TSH is often the starting laboratory measurement for primary thyroid dysfunction. Free T4 can help clarify an abnormal result or a situation in which the usual relationship between the two is unreliable. A thyroid abnormality may contribute to symptoms, but it should not end the neurological evaluation if the symptom pattern remains unexplained. [6]
Kidney information has two roles here: assessing an important comorbidity and interpreting markers affected by clearance. Mildly reduced filtration does not automatically explain neuropathy. See the thyroid blood test guide and kidney function testing guide for their broader interpretation frameworks.
The Brain and Neurological Blood Tests guide explains how laboratory testing fits alongside clinical assessment. Broad panels can introduce findings unrelated to the symptoms; choose each addition because its answer could change care.
Use the report's units and reference intervals, but ask what decision the result addresses. A reference flag is not a diagnosis. Comparing results obtained under similar conditions is often more informative than comparing a single value with a number found online.
| Illustrative pattern | Question for clinical review |
|---|---|
| Indeterminate B12, normal CBC, persistent tingling | Would MMA clarify deficiency, and are there competing neurological explanations? |
| Elevated MMA and reduced kidney filtration | How much could reduced clearance explain the elevation? |
| A1C at the individual's goal, ongoing foot numbness | Could previous nerve injury or a separate condition account for symptoms? |
| Thyroid results improve, but weakness progresses | Does the progression require neurological reassessment? |
These are educational patterns, not diagnostic rules. A1C can also be affected by red-cell turnover and some hemoglobin conditions. If it conflicts with home glucose records, ask which evidence best reflects current glycemia. [7]
Follow instructions for the exact laboratory order. A1C and CBC alone ordinarily do not require fasting, but another component of a combined order may. Anyone using insulin should have a safe plan if fasting is requested.
Report vitamin tablets, injections, multivitamins, biotin, prescribed medicines, and when replacement treatment began. Do not stop treatment or delay care for significant neurological symptoms merely to obtain an untreated baseline. Bring earlier reports and a short symptom timeline.
Follow-up should track function as well as numbers: sleep disrupted by pain, walking, balance, injuries, and ability to perform daily activities. A rising vitamin concentration does not prove that nerve function has recovered. Persistent symptoms may need a revised explanation or specialist input.
Eligible patients can explore individual laboratory options online, review displayed pricing and preparation requirements, and use results to support a healthcare visit. Availability and collection arrangements can vary. Check for duplicate measurements before combining products, and arrange who will interpret the findings.
A focused order may be more useful than a large panel. Learn about the ordering and follow-up process in Direct-Access Lab Testing. Testing supports the evaluation; it cannot replace an examination, wound care, or treatment decisions.
No. Diabetes is a common context for nerve symptoms, but vitamin deficiency, thyroid disease, kidney disease, nerve compression, and other neurological conditions can contribute. The distribution, speed of onset, examination, and medical history help determine what to investigate. A person can also have diabetic neuropathy and a second condition at the same time.
Yes. Nerve symptoms can occur without anemia or enlarged red cells. A normal CBC therefore does not settle the question when symptoms and risk factors suggest deficiency. A clinician interprets the vitamin B12 test with treatment history and may use MMA when the initial result leaves a meaningful uncertainty.
No. MMA is most useful when it clarifies a specific uncertainty, such as an indeterminate B12 result with compatible symptoms. It is not an automatic addition to every diabetes visit. Reduced kidney clearance can elevate it, so a clinician should consider kidney information before treating an isolated elevation as proof of deficiency.
No. A1C reflects recent glucose exposure and cannot show previous nerve injury, nerve compression, or a vitamin-related problem. It also does not describe daily glucose variability. Ongoing symptoms deserve examination even when the result meets the individual's treatment goal. A reassuring number should support care, not replace investigation of a changing symptom.
Not necessarily. Thyroid dysfunction may contribute, but a result must fit the clinical picture. TSH and selected free T4 help assess thyroid function, while the neurological examination addresses the symptom pattern. If symptoms persist or worsen after thyroid treatment, the clinician may need to look for another or an additional cause.
Discuss symptoms and supplements with a healthcare professional first. Starting supplements can complicate interpretation, and vitamin products do not treat every cause of neuropathy. Significant or progressive neurological symptoms need prompt care. Do not stop prescribed replacement or postpone necessary treatment simply to obtain a baseline blood sample for an online order.
No. Blood tests can investigate contributing conditions, but they do not directly test every aspect of nerve function. A clinician may still diagnose neuropathy from history and examination or recommend further studies. Persistent loss of sensation, pain, imbalance, or weakness warrants follow-up even when the initial laboratory results fall within their reference intervals.
There is no universal repeat panel for tingling. Timing depends on the suspected cause, initial abnormalities, treatment, and symptom course. A due A1C may fit routine diabetes care, while vitamin or thyroid follow-up answers a different question. Ask which result will guide the next decision and which symptoms should prompt earlier review.
A useful evaluation connects symptoms, examination, diabetes history, and selected laboratory findings. Discuss whether vitamin B12 testing, CBC, thyroid testing, kidney assessment, or a due A1C could answer your specific question. Explore the linked Ulta options with a plan for clinical review and follow-up.
Numbness and tingling with diabetes can reflect diabetic neuropathy or another neurological, nutritional, thyroid, or kidney-related condition. Selected blood tests identify possible contributors while examination establishes the clinical pattern.
Relevant tests: Vitamin B12 test, selected MMA, CBC, TSH, selected free T4, creatinine with reported eGFR, and A1C.
Ulta Lab Tests provides access to relevant laboratory options for eligible patients to discuss with a healthcare professional.
Educational information only; laboratory results require clinical interpretation and do not replace individualized medical care.
| Category | Linked tests and role |
|---|---|
| Vitamin assessment | Vitamin B12 — evaluates a potentially treatable contributor to nerve symptoms. |
| Additional B12 clarification | Methylmalonic Acid — a conditional addition when B12 results and symptoms need clarification; kidney function affects interpretation. |
| Blood-cell assessment | CBC with Differential and Platelets — provides anemia and blood-cell context. |
| Thyroid assessment | TSH, with selected Free T4. |
| Kidney assessment | Creatinine — interpreted with reported eGFR and clinical context. |
| Diabetes monitoring | Hemoglobin A1C — assesses longer-term glucose exposure; it does not establish the cause of neuropathy. |
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
